Skip to content
TESCT — Trans European Stem Cell Therapy Society

Society members

Seline Hofer

Member — Paediatric Neurology

  • Cand. Med.

Seline Hofer's research addresses the management of acute demyelinating attacks in the Swiss paediatric population. The management of an acute demyelinating attack in children is based on personal experience and expert opinion: while the majority would agree to treat an acute demyelinating attack with i.v. steroids, there is little consensus on whether to taper or not with oral prednisone.

Demyelinating diseases are distinct entities amongst the inflammatory brain diseases. Myelin — the substantial part of the white matter of the CNS — is the target of the acute demyelinating attack. The most common acquired demyelinating syndromes (ADS) are optic neuritis, transverse myelitis and acute disseminated encephalomyelitis. The incidence of an acquired demyelinating syndrome in childhood is 1/100,000, with approximately 25% of these patients being diagnosed with multiple sclerosis over the following 2–5 years.

Evidence based guidelines regarding the treatment of acute demyelinating attacks in the paediatric population are lacking. A consensus statement based on expert opinions recommends the use of high dose (20–30 mg/kg/day) i.v. methylprednisolone for 3–5 days in the case of an acute demyelinating attack. However, there is clinical equipoise about whether an oral prednisone taper following the i.v. treatment has any influence on outcome.

In summary, the treatment regimen of an acute demyelinating attack in the paediatric population — especially the role of an oral prednisone taper — needs further assessment. The aim of this work is to identify and distinguish patients who will benefit from prolonged steroid treatment from those where a prednisone taper is unnecessary.

Research questions

  • Does an oral prednisone taper have any beneficial influence on outcome in paediatric patients suffering from an acute demyelinating attack?
  • Which patients with an acute demyelinating attack will benefit from an oral prednisone taper?
  • Does the taper influence relapse frequency, disability or brain atrophy?

Areas of work

  • Paediatric neurology
  • Demyelinating disease
  • Clinical research